Category Archives: Clay Siegall Leadership

Clay B. Siegall Gives An Overview Of Seattle Genetics’ Present and Future

Dr. Clay Siegall, the president and CEO of Seattle Genetics, took a journey of Seattle Genetics and shed light on what the future holds for the company. While giving an opening keynote presentation at CHI’s 5th Annual Antibody-Drug Conjugates Conference, Clay Siegall discussed about the company’s plans in the field of ADCs. Seattle Genetics’ ADCETRIS is the first drug to be manufactured under the field of ADCs. It has been used in treatment of over 15,000 lymphoma cases in the world. This analysis increases the possibility of the drug being used as the forefront therapy for CD3-expressing malignancies. The cancer institute is currently undertaking phase 3 clinical trials of ADCETRIS known as ALCANZA, ECHELON-1 and ECHELON-2. The company is looking forward to reporting data of the first phase in 2016. Clay posited that they expect to finish enrollment and data readouts of the remaining two phases by 2018. This information was originally published on Mirna Therapeutics’s website.

After manufacturing ADCETRIS, the company will proceed to designing 7 clinical-stage programs where the major ADC programs will be SGN-CD33A for acute myeloid leukemia and SGN-CD19A for non-Hodgkin lymphoma. Seattle Genetics will also introduce an internalizing antibody. Seattle has 17 years’ experience in the ADC industry. Clay said that he was excited about the two major pipeline programs. SGN-CD33A is designed to remain stable in the bloodstream and only releases its cytotoxic agent once it is internalized into CD33-expressing cells. SGN-CD19A is also built to stabilize while in the bloodstream. After internalizing into CD19-expressing tumor cells, it releases its cytotoxic agent. He concluded by saying that positive results have been recorded from ongoing clinical trials. The company is planning to conduct a randomized phase 2 trial of CD19A together with R-ICE chemotherapy.
Clay B. Siegall is the co-founder and the chairman of the Board of Directors of Seattle Genetics. He has provided servant leadership to Seattle Genetics. He has enabled the employees to build a large pipeline of antibody-based therapies for cancer, including the reigning ADCETRIS that was approved by FDA in 2011. Under his leadership, the company has secured over $675 million through private and public funding. Clay B. Siegall has worked for different companies, including Bristol Myers Squibb Pharmaceutical Research Institute, Institutes of Health and National Cancer institute. The author of over 70 publications is an alumnus of the esteemed George Washington University. This information was originally mentioned on Crunch Base.